Abstract: A composition in the form of an injectable aqueous solution, whose pH consists from 6.0 to 8.0, including at least: a basal insulin whose isoelectric point includes from 5.8 to 8.

Abstract: The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide.

Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.

Abstract: A skin care composition that includes a combination of palmitoyl dipeptide-7, acetyl tetrapeptide-11, other optional skin ingredients, and a dermatologic ally acceptable carrier. The combination of peptides synergistically improves cellular ATP level and/or upregulates the expression of peroxisome proliferator activated receptor alpha and/or methylsterol monooxygenase 1 to help provide improved skin health and appearance.

Abstract: The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.

Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Abstract: Disclosed is a new class of conjugated virus-like particles (VLPs). These conjugated VLPs bind a wide variety of tumors and comprise epitopes recognized by a prior T cell immune response already existing in a host. These epitopes are derived from pathogens or previous vaccinations (such as early childhood vaccines). This provokes the body's pre-existing cytotoxic immunity obtained through previous infection or previous childhood vaccination to be redirected to the tumor cells for the elimination of cancer, and form long-term anti-tumor immunity. The described conjugated VLPs are useful for tailoring a broad range of tumors towards a response from existing immunity circumventing the need to identify tumor antigens or generate tumor-specific immune responses.

Abstract: Provided herein are bioconjugates comprising a backbone and at least one branched or unbranched peptide having at least one collagen-binding unit covalently bonded thereto via a spacer and methods of use thereof.

Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NO: 1], or a variant thereof, are described.

Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.

Abstract: A method for preventing aging of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and includes at least one amino acid sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 6. Each of the amino acid sequence is a peptide of fish skin. The composition has anti-aging and cellular health maintaining capabilities. In addition, the composition can also be used for increasing collagen content, improving skin collagen density, improving skin moisture, minimizing skin pores, reducing wrinkles or achieving a combination of these effects.

Abstract: A hyperglycosylated recombinant human coagulation factor IX (FIX) fusion protein, a preparation method therefor, and use thereof. The fusion protein sequentially comprises, from N- to C-terminus, a human FIX, a flexible peptide linker, at least one human chorionic gonadotropin ? subunit carboxy-terminal peptide rigid unit, and a half-life extending moiety. The fusion protein has a biological activity similar to that of the recombinant FIX, an extended in vivo activity half-life, and reduced immunogenicity, so as to improve pharmacokinetics and pharmacodynamics.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Abstract: Disclosed herein is a cyclic peptide polymer. R1, R2, and R3 are organic groups. Each R4 is a covalent bond, methylene, ethylene, n-propylene, or n-butylene. Each X is —NH—, —O—, or —O—CO—. The values m and n are nonnegative integers having a sum of at least 1. The value p is an integer greater than 1. The cyclic peptide polymer may be made by providing a first cyclic peptide monomer having a protecting group on the X group, covalently binding the —CO—OH group of the first cyclic peptide monomer to a solid support having a carboxylic acid-reactive group, converting the protecting group to —XH, reacting the —XH group with the —CO—OH group of an additional cyclic peptide monomer, optionally repeating the converting and reacting steps with further additional cyclic peptide monomers, and cleaving the cyclic peptide polymer from the solid support.

Abstract: The present invention relates to compositions that are effective in management of inflammatory diseases. The disclosure provides a peptide complex comprising Abeta 1-42 and undercarboxylated osteocalcin which displays anti-inflammatory and immunomodulatory functions. The disclosure further provides with processes for preparing the compositions.

Abstract: The present invention describes methods of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a medical condition related to ischemia/reperfusion in a subject using GJA1-20k as a therapeutic agent. The invention further provides a method of protecting a cell from metabolic stress, using GJA1-20k. The invention also provides for a composition and/or gene expression vector comprising GJA1-20k.

Abstract: The present invention relates to: a novel peptide having activity of preventing skin damage caused by pollutants, and skin anti-aging and wrinkle alleviation activities; and a use of the peptide, which is related to the prevention or treatment of diseases caused by pollutants or to the improvement of skin anti-aging. Particularly, the novel peptide of the present invention inhibits the inflow, into skin cells, of pollutants such as dioxin, particulate matter, and cigarette smoke, and regulates the expression of a skin aging-related gene, and thus may be effectively used as an active ingredient of a pharmaceutical composition for preventing or treating cancer, skin diseases, and lung diseases, which are caused by pollutants, or skin aging-related diseases, or as an active ingredient of a cosmetic composition for preventing skin damage caused by pollutants or for a skin anti-aging effect.

Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.

Abstract: Disclosed are compounds, compositions, and methods involving cyclic peptides that can bind to KRAS (G12D) oncogenic protein. For example, disclosed are cyclic peptides that selectively bind KRAS (G12D) oncogenic protein. Also disclosed are methods of inhibiting KRAS (G12D) oncogenic protein in a cancer cell expressing KRAS (G12D) oncogenic protein. In some forms, the method comprises incubating the cancer cell with any one or more of the disclosed cyclic peptides. In some forms, the method comprises bringing into contact the cancer cell with any one or more of the disclosed cyclic peptides.